AI-Driven Agentic Design Platform for Tumor Immunotherapy Drugs

Joint ZGCA + ZGCI flagship announcement: an agentic AI platform that autonomously identifies optimal drug design objectives and generates candidate molecules for tumor immunotherapy. Integrates biomedical knowledge with generative AI in an end-to-end workflow.

The platform's lead candidate, Z212 — entirely AI-generated — achieved 83.7% tumor growth inhibition (TGI) in MC38 humanized mouse efficacy models, significantly outperforming PD-1/PD-L1 comparisons. Z212 has advanced to Preclinical Candidate (PCC) stage. The full workflow from sequence to validation was compressed from years to 6 months, demonstrating dramatic acceleration of drug discovery timelines via AI agents.